JZP-110 is an investigational drug.
There have been 11 clinical trials for JZP-110.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2015.
The most common disease conditions in clinical trials are Sleepiness, Narcolepsy, and Disorders of Excessive Somnolence. The leading clinical trial sponsors are Jazz Pharmaceuticals, Concert Pharmaceuticals, and Children's Oncology Group (COG).
There are thirty-nine US patents protecting this investigational drug and two hundred and eighty-one international patents.